Who Paid My Doc
Ramona Dadu
Endocrinology, Diabetes & Metabolism Houston, TX Medical Doctor
NPI 1629229554 CMS profile 164885
1515 Holcombe Blvd, Unit 1461, Houston, TX 77030
General payments
$5,422
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$155,001
Through program year 2025, Ramona Dadu of Houston, TX is reported in the CMS Open Payments database as having received $5,422 across 11 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $155,001 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 69th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $140 | 1 | |
| 2024 | General | $26 | 1 | |
| 2023 | General | $1,000 | 1 | |
| 2021 | General | $2,970 | 4 | |
| 2020 | General | $1,152 | 3 | |
| 2019 | General | $134 | 1 |
Beside peers
- Ramona Dadu
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Ramona Dadu were reported at $140. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Ramona Dadu | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $134 | $494 | $123–$2,253 | $163 |
| 2020 | $1,152 | $335 | $85–$1,841 | $114 |
| 2021 | $2,970 | $398 | $88–$1,981 | $132 |
| 2022 | $0 | $364 | $88–$1,568 | $149 |
| 2023 | $1,000 | $420 | $113–$1,614 | $160 |
| 2024 | $26 | $440 | $121–$1,646 | $164 |
| 2025 | $140 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
215
Drug cost
$1,466,432
Branded share of claims
62.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mekinist Trametinib Dimethyl Sulfoxide | Brand | 56 | $757,760 | |
| Tafinlar Dabrafenib Mesylate | Brand | 54 | $644,770 | |
| Everolimus | Generic | 14 | $61,212 | |
| Synthroid Levothyroxine Sodium | Brand | 25 | $2,081 | |
| Levothyroxine Sodium | Generic | 52 | $451 | |
| Prochlorperazine Maleate | Generic | 14 | $158 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$32,096
Medicare patients
212
Services billed
354
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 55% | |
| Ischemic heart disease | 40% | |
| Cancer | 40% | |
| Diabetes | 38% | |
| Chronic kidney disease | 33% | |
| COPD | 24% | |
| Depression | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
11 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Texas
Lance Sloan
Endocrinology, Diabetes & Metabolism · Lufkin, TX
Pablo Mora
Endocrinology, Diabetes & Metabolism · Dallas, TX
Robert Hood
Endocrinology, Diabetes & Metabolism · Beaumont, TX
Eduardo Luna
Endocrinology, Diabetes & Metabolism · Edinburg, TX
Steve Fordan
Endocrinology, Diabetes & Metabolism · Dallas, TX
Rosemarie Lajara
Endocrinology, Diabetes & Metabolism · Plano, TX
Related records
Endocrinology, Diabetes & Metabolism in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.